

Nepal Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Grant number(s): 1819-NPL-09a-X; 17-NPL-09a-X; 15-NPL-08d-Y; 13-NPL-08e-Y			
3. Date of Decision Letter: 27 March 2019			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: New Vaccine Support (NVS), Measles-Rubella Second Dose routine - strat 1			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2015 -2019			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2015-2018	2019	Total ²
Programme Budget (US\$)	800,702 ³	US\$237,000	US\$1,037,702
10. Vaccine introduction grant (in US\$):			
	2013	2015	
	US\$554,500 disbursed on 28 May 2013	US\$546,500 disbursed on 28 May 2015	
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015-2018	2019	
Number of Measles-Rubella vaccines doses		760,900	
Annual Amounts (US\$)	800,702 ⁵	237,000	
12. Procurement agency: UNICEF Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			
14. Co-financing obligations: According to the co-financing policy, Country falls within the group Initial self-financing. Please refer to the line 17 below.			
15. Operational support for campaigns: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

Requirements	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. <p>Countries shall report the actual switch date in the first renewal request following the actual implementation.</p>	<p>31 March 2019 15 May 2019</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Other conditions:

Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2019
Number of doses of vaccines for Measles Second Dose approved by Gavi.	760,900
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	232,835
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	363,805
Number of doses of Measles-Rubella vaccine to be funded by country.	397,095
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	254,141

In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.

In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
27 March 2019